Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

60.92 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
NEKTAR THERAPEUTICS (NASDAQ:NKTR) Q4 2025 Earnings: Revenue Surges 105% Above Estimates ↗
Via Chartmill
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKTR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Law Offices of Frank R. Cruz Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Law Offices of Howard G. Smith Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Nektar (NKTR) Q4 2025 Earnings Call Transcript ↗
Nektar (NKTR) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Nektar Therapeutics (NKTR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With Large Losses in Nektar Therapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims
From Grabar Law Office
Via GlobeNewswire
News headline image
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NKTR
From DJS Law Group
Via Business Wire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
NKTR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire... 
Via Finterra
Topics Lawsuit
Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts ↗
The company reported that complete skin clearance rates increased twofold to fivefold during the maintenance phase of the trial. 
Via Stocktwits
Top stock movements in today's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.